Loading...
•
Mar 31, 2025
•/
Aurora Cannabis Q4 2025 Earnings Report
Aurora Cannabis reported strong Q4 performance, highlighted by significant growth in medical cannabis revenue and profitability metrics.
Key Takeaways
Aurora Cannabis delivered a 34% year-over-year increase in net revenue in Q4 2025, driven by international medical cannabis sales and improved margins. Despite a net loss, adjusted EBITDA grew substantially, and the company generated positive free cash flow.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Aurora expects modest revenue pressure in Q1 FY26 due to seasonality and temporary declines in international markets but foresees recovery in later quarters with continued profitability.
Positive Outlook
- Strong Canadian medical performance expected to continue
- Stable consumer cannabis revenue forecasted
- International revenues expected to rebound in later quarters
- Margins projected to remain strong
- Positive free cash flow expected to continue
Challenges Ahead
- Slight decline in total cannabis revenue expected in Q1 FY26
- Lower revenue from high-margin international markets
- Expected decline in adjusted EBITDA compared to Q4
- Seasonal impacts affecting plant propagation
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...